In a phase II study conducted by Madrigal Pharmaceuticals, it was observed that patients who were administered Resmetirom experienced notable reductions in PRO-C3 and MRI-PDFF levels[5]. This study involved patients who were initially divided into two groups: one receiving a placebo (Pbo) and the other receiving Resmetirom (Res) for a duration of 36 weeks. Subsequently, all participants continued with Resmetirom in the open-label extension (OLE) trial for an additional 36 weeks (Figure 3). |  Figure 3. PRO-C3 is used as a determinant of treatment efficacy in multiple clinical trials as a secondary endpoint for antifibrotic efficacy[5] |
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
